blank
blank

National Action Plan for Rare Diseases in Austria

1:1
Austria’s national strategy defining priority areas and concrete measures to improve care, research, and access to services for people living with rare diseases.

This publication presents Austria’s National Action Plan for Rare Diseases (NAP.se), developed on behalf of the Federal Ministry of Health. It defines nine strategic action areas covering governance, diagnosis, clinical care, research, information systems, patient involvement, and access to therapies, including objectives, proposed measures, responsible stakeholders, and indicative timelines. The publication is available in German only.

Acces this publication (pdf)
Nationale Aktionsplan für seltene Erkrankungen

Year of publication

2015

ISBN

978-3-85010-538-5

Source

Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (Austria), Austrian Public Health Institute (Gesundheit Österreich GmbH – GÖG), National Coordination Centre for Rare Diseases (NKSE)

Author

Florian Bachner; Margit Gombocz; Claudia Habl; Joy Ladurner; Christine Leopold; Ursula Unterberger; Till Voigtländer

You might also be interested in

Female scientist in protective gear using lab equipment for research.. Photo by ima Miroshnichenko via Pexels (CC0)

Biotech Act II: European Commission opens Call for Evidence on industrial biotechnology and biomanufacturing

The European Commission has opened a Call for Evidence on the upcoming Biotech Act II — with feedback open until 10 June 2026, inviting stakeholders to submit input that will help shape the initiative before a legislative proposal is prepared.
ERDERA workshop (3)

Webinar: The ERDERA Diagnostic Research Workstream – An overview

The session will introduce the workstream’s activities in data sharing, systematic diagnostic reanalysis, advanced diagnostic pipelines, and genomic and multi-omics innovation.
ERDERA First Policy Think Tank meeting

ERDERA Policy Think Tank meets in Paris to advance data and registry policy for rare diseases

Bringing together policy makers, researchers and data experts to align on how registry data can better support rare disease research and evidence‑based policy across Europe.
kitt_ks-lab-2107514_1920

Towards animal-free testing: virtual control groups gain regulatory acceptance

For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.

ERDERA's

search form